Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Caliway Biopharmaceuticals Co., Ltd. (6919:TWSE), powered by AI.
Caliway Biopharmaceuticals Co., Ltd. is currently trading at $611.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Caliway Biopharmaceuticals Co., Ltd. on Alpha Lenz.
Caliway Biopharmaceuticals Co., Ltd.'s P/E ratio is -155.0.
“Caliway Biopharmaceuticals Co., Ltd. trades at a P/E of -155.0 (undervalued) with modest ROE of -19.9%.”
Ask for details →Caliway Biopharmaceuticals Co., Ltd. is a company specializing in the development and commercialization of innovative pharmaceutical products. Its primary function is to advance medical treatments through its robust pipeline of therapies, focusing on unmet medical needs in areas such as dermatology, neurology, and oncology. The biopharmaceutical firm aims to transform cutting-edge research into accessible healthcare solutions, with a particular emphasis on injectable treatments and small molecule drugs. Caliway Biopharmaceuticals operates within the highly dynamic and competitive biotechnology and pharmaceuticals sector, which is crucial for advancing medical science and improving patient outcomes. Its significant role in the market lies in its focus on innovation and addressing niche therapeutic areas, which can generate substantial benefits for the healthcare community as well as providing solutions that potentially improve quality of life. Headquartered in a strategic location with access to research facilities and partnerships, Caliway Biopharmaceuticals embodies a commitment to pushing the boundaries of modern medicine.
“Caliway Biopharmaceuticals Co., Ltd. trades at a P/E of -155.0 (undervalued) with modest ROE of -19.9%.”
Ask for details →Caliway Biopharmaceuticals Co., Ltd. (ticker: 6919) is a company listed on TWSE in the Healthcare sector (Biotechnology). Market cap is $75.7B.
The current price is 611 with a P/E ratio of -154.97x and P/B of 20.23x.
ROE is -19.92% and operating margin is -1318.88%. Annual revenue is $39M.